AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Frugivorous bats lack that ability and have kidneys adapted for electrolyte retention due to their low-electrolyte diet; their kidneys accordingly have a thick cortex and very short conical papillae. Flying gives bats relatively high metabolism, which increases respiratory water loss. Lipids known as cerebrosides retain water in cold temperatures but allow for evaporation through the skin in hot temperatures to cool them. Water helps maintain the ionic balance in their blood, thermoregulation system and urinary and waste system. They are also susceptible to blood urea poisoning if they do not receive enough fluid. The structure of the uterine system in female bats can vary by species, with some having two uterine horns while others have a single mainline chamber.
Nerve endings in the vagina can provide pleasurable sensations when they are stimulated during sexual activity. Women may derive pleasure from one part of the vagina, or from a feeling of closeness and fullness during vaginal penetration. Because the vagina is not rich in nerve endings, women often do not receive sufficient sexual stimulation, or orgasm, solely from vaginal penetration. Although the literature commonly cites a greater concentration of nerve endings and therefore greater sensitivity near the vaginal entrance (the outer one-third or lower third), some scientific examinations of vaginal wall innervation indicate no single area with a greater density of nerve endings. Other research indicates that only some women have a greater density of nerve endings in the anterior vaginal wall. Because of the fewer nerve endings in the vagina, childbirth pain is significantly more tolerable. Pleasure can be derived from the vagina in a variety of ways. In addition to penile penetration, pleasure can come from masturbation, fingering, or specific sex positions (such as the missionary position or the spoons sex position). Heterosexual couples may engage in fingering as a form of foreplay to incite sexual arousal or as an accompanying act, or as a type of birth control, or to preserve virginity. Less commonly, they may use non penile-vaginal sexual acts as a primary means of sexual pleasure. In contrast, lesbians and other women who have sex with women commonly engage in fingering as a main form of sexual activity.
This conversion occurs during the liming process, before introduction of the tanning agent (chromium salts). Later during pickling, collagen carboxyl groups are temporarily protonated for ready transport of chromium ions. During basification step of tanning, the carboxyl groups are ionized and coordinate as ligands to the chromium(III) centers of the oxo-hydroxide clusters. Tanning increases the spacing between protein chains in collagen from 10 to 17 Å. The difference is consistent with cross-linking by polychromium species, of the sort arising from olation and oxolation.
Sources: en.wikipedia.org
Thorium is still used as an alloying element in TIG welding electrodes but is slowly being replaced in the field with different compositions. It was also material in high-end optics and scientific instrumentation, used in some broadcast vacuum tubes, and as the light source in gas mantles, but these uses have become marginal. It has been suggested as a replacement for uranium as nuclear fuel in nuclear reactors, and several thorium reactors have been built. Thorium is also used in strengthening magnesium, coating tungsten wire in electrical and welding equipment, controlling the grain size of tungsten in electric lamps, high-temperature crucibles, and glasses including camera and scientific instrument lenses. Other uses for thorium include heat-resistant ceramics, aircraft engines, and in light bulbs. Ocean science has used 231Pa/230Th isotope ratios to understand the ancient ocean.
== Interactions == Lixisenatide and other GLP-1 receptor agonist slow emptying of stomach contents, which may affect the absorption of orally administered medications. For effective use, oral contraceptives should be taken 1 hour before or 11 hours after taking lixisenatide-containing products. Acetaminophen and antibiotics are among other drugs that are affected by this action of lixisenatide.
On October 10, Trump had another visit with Walter Reed. Leavitt described the visit as a "routine yearly checkup", despite it being Trump's second at the facility in a six-month-period. Barbabella did not elaborate on the imaging or "preventive assessments" that he performed, but added that Trump's laboratory results were "exceptional," and that his cardiac age is "approximately 14 years younger than his chronological age." On October 27, Trump told reporters that he had undergone an undisclosed MRI scan during a previous visit to Walter Reed, which, despite his claim that it gave "some of the best reports for the age" and "some of the best reports they've ever seen", led to further speculation about his health due to the undisclosed nature of why he had the procedure done. Trump also bragged about his taking of the MoCA test, again misidentifying the screening assessment for detecting cognitive impairment as a "very hard [...] IQ test" and claiming that younger Democratic political opponents do not have the intelligence to pass it. Whether a third MoCA test was conducted during the October visit or if Trump was referring to his April 2025 and/or January 2018 assessments was not clarified. On October 28, new concerns about Trump's mental state were raised when a video emerged of him wandering off while walking alongside Sanae Takaichi, the first female prime minister of Japan, while at Akasaka Palace in Tokyo, Japan.
True Health Diagnostics was founded by Chris Grottenthaler in March 2014 in Frisco, Texas, a clinical laboratory company to sell and develop medical tests. Grottenthaler had formerly worked in private equity. True Health was CLIA certified in Texas in August 2014 and offered its first tests in October of that year. True Health hired several sales representatives who had worked for BlueWave, a contract sales organization. However, True Health did not hire any of the owners or leadership of BluWave In September 2015 True Health purchased the assets of a bankrupt competing company, Health Diagnostic Laboratory, Inc. at a court-supervised auction for $37.1 million. HDL had around 550 employees in Richmond, Virginia, and had gone bankrupt after a $47 million settlement with the US Department of Justice over allegations that HDL had bribed doctors to send business its way; True Health assumed a corporate integrity agreement that HDL had signed as part of the settlement. HDL had run sales through BlueWave, and BlueWave had been named as a party in the DoJ Investigation; HDL had split with BlueWave in January 2015 during the investigation, and in April, before it filed for bankruptcy, HDL had tried to get a court to examine whether the former BlueWave employees working with True Health were interfering with HDL's business. As of November 2015 True Health had retained about 350 of HDL's employees in Richmond and was processing samples in HDL's former CLIA facility.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.